Intravenous metoprolol during ongoing STEMI ameliorates markers of ischemic injury: a METOCARD-CNIC trial electrocardiographic study
- 19 July 2021
- journal article
- research article
- Published by Springer Nature in Basic Research in Cardiology
- Vol. 116 (1) , 1-15
Abstract
Besides its protective effect against neutrophil-mediated injury at reperfusion, intravenous (IV) metoprolol was recently shown to reduce the progression of ischemic injury in a pig model of ST-segment elevation myocardial infarction (STEMI). Here, we tested the hypothesis that IV metoprolol administration in humans with ongoing STEMI blunts the time‑dependent progression of ischemic injury assessed by serial electrocardiogram (ECG) evaluations before reperfusion. The METOCARD-CNIC trial randomized 270 anterior STEMI patients to IV metoprolol or control before reperfusion by percutaneous coronary intervention (PCI). In 139 patients (69 IV metoprolol, 70 controls), two ECGs were available (ECG-1 before randomization, ECG-2 pre-PCI). Between-group ECG differences were analyzed using univariate and multivariate regression models. No significant between-group differences were observed on ECG-1. On ECG-2, patients who received IV metoprolol had a narrower QRS than those in the control group (84 ms vs. 90 ms, p = 0.029), a lower prevalence of QRS distortion (10% vs. 26%, p = 0.017), and a lower sum of anterior and total ST-segment elevation (10.1 mm vs. 13.6 mm, p = 0.014 and 10.4 mm vs. 14.0 mm, p = 0.015, respectively). Adjusted analysis revealed similar results. Significant associations were observed between ECG-2 variables and cardiac magnetic resonance imaging measurements (extent of myocardial edema, infarct size, microvascular obstruction, and left-ventricular ejection fraction) after STEMI. In summary, IV metoprolol administration before reperfusion ameliorates ECG markers of myocardial ischemia in anterior STEMI patients. These data confirm that IV metoprolol is able to reduce ischemic injury and highlight the ability of ECG analysis to provide relevant real-time information on the effect of cardioprotective therapies before reperfusion.Keywords
Funding Information
- Ministerio de Ciencia e Innovación (RETOS2019-107332RB-I00)
This publication has 41 references indexed in Scilit:
- Cardioprotective Role of Remote Ischemic Periconditioning in Primary Percutaneous Coronary InterventionJACC: Cardiovascular Interventions, 2010
- Effects of ischemic preconditioning and arterial collateral flow on ST-segment elevation and QRS complex prolongation in a canine model of acute coronary occlusionJournal of Electrocardiology, 2009
- ST-Segment Recovery and Outcome After Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial InfarctionCirculation, 2008
- The value of both ST-segment and QRS complex changes during acute coronary occlusion for prediction of reperfusion-induced myocardial salvage in a canine modelJournal of Electrocardiology, 2007
- Usefulness of Quantitative Baseline ST-Segment Elevation for Predicting Outcomes After Primary Coronary Angioplasty or Fibrinolysis (Results from the DANAMI-2 Trial)The American Journal of Cardiology, 2006
- Single lead ST-segment recovery: a simple, reliable measure of successful fibrinolysis after acute myocardial infarctionAmerican Heart Journal, 2004
- Attenuation of S-T Segment elevation during repetitive coronary occlusions truly reflects the protection of Ischemic preconditioning and is not an epiphenomenonBasic Research in Cardiology, 1997
- Short-term effects of early intravenous treatment with a beta-adrenergic blocking agent or a specific bradycardiac agent in patients with acute mycardial infarction receiving thrombolytic therapyJACC, 1993
- Adaptation to ischemia during percutaneous transluminal coronary angioplasty. Clinical, hemodynamic, and metabolic features.Circulation, 1990
- β‐Adrenoceptor blockers and the blood‐brain barrierBritish Journal of Clinical Pharmacology, 1981